Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflamatory consequences
Authors:ID Govednik, Tea (Author)
ID Lainšček, Duško (Author)
ID Kuhar, Urška (Author)
ID Lachish, Marva (Author)
ID Janežič, Sandra (Author)
ID Štrbenc, Malan (Author)
ID Krapež, Uroš (Author)
ID Jerala, Roman (Author)
ID Atlas, Daphne (Author)
ID Manček Keber, Mateja (Author), et al.
Files:URL URL - Source URL, visit https://www.sciencedirect.com/science/article/pii/S0166354224000147?via%3Dihub
 
.pdf PDF - Presentation file, download (7,11 MB)
MD5: C082D1D70D9C5216904459B7957D861A
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo KI - National Institute of Chemistry
Abstract:After three years of the SARS-CoV-2 pandemic, the search and availability of relatively low-cost benchtop therapeutics for people not at high risk for a severe disease are still ongoing. Although vaccines and new SARS-CoV-2 variants reduce the death toll, the long COVID-19 along with neurologic symptoms can develop and persist even after a mild initial infection. Reinfections, which further increase the risk of sequelae in multiple organ systems as well as the risk of death, continue to require caution. The spike protein of SARS-CoV-2 is an important target for both vaccines and therapeutics. The presence of disulfide bonds in the receptor binding domain (RBD) of the spike protein is essential for its binding to the human ACE2 receptor and cell entry. Here, we demonstrate that thiol-reducing peptides based on the active site of oxidoreductase thioredoxin 1, called thioredoxin mimetic (TXM) peptides, can prevent syncytia formation, SARS-CoV-2 entry into cells, and infection in a mouse model. We also show that TXM peptides inhibit the redox-sensitive HIV pseudotyped viral cell entry. These results support disulfide targeting as a common therapeutic strategy for treating infections caused by viruses using redox-sensitive fusion. Furthermore, TXM peptides exert anti-inflammatory properties by lowering the activation of NF-κB and IRF signaling pathways, mitogen-activated protein kinases (MAPKs) and lipopolysaccharide (LPS)-induced cytokines in mice. The antioxidant and anti-inflammatory effects of the TXM peptides, which also cross the blood-brain barrier, in combination with prevention of viral infections, may provide a beneficial clinical strategy to lower viral infections and mitigate severe consequences of COVID-19.
Keywords:SARS-CoV-2, Disulfides, Thiol-reacting compound, Spike, Anti-inflammatory activity
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2024
Publisher:Elsevier
Year of publishing:2024
Number of pages:str. 1-13
Numbering:Vol. 222, [article no.] ǂ105806
Source:Antiviral Research
PID:20.500.12556/DiRROS-18097-f3ed862f-7f85-7b25-18eb-c96d6b18fb22 New window
UDC:577:616
ISSN on article:1872-9096
DOI:10.1016/j.antiviral.2024.105806 New window
COBISS.SI-ID:181304579 New window
Copyright:© 2024 The Authors. Published by Elsevier B.V.
Note:Št. članka: 105806;
Publication date in DiRROS:06.02.2024
Views:326
Downloads:136
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Antiviral research
Shortened title:Antivir. res.
Publisher:Elsevier Science
ISSN:1872-9096
COBISS.SI-ID:34758873 New window

Document is financed by a project

Funder:ARRS - Slovenian Research Agency
Project number:V4-2038
Name:DNK cepiva in peptidnih inhibitorji proti SARS-CoV-2

Funder:ARRS - Slovenian Research Agency
Project number:P4-0176
Name:Sintezna biologija in imunologija

Funder:ARRS - Slovenian Research Agency
Project number:P4-0092
Name:Zdravje živali, okolje in varna hrana

Funder:ARRS - Slovenian Research Agency
Project number:P4-0053
Name:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Funder:EC - European Commission
Funding programme:H2020
Project number:899619
Name:General-purpose virus-neutralizing engulfing shells with modular target-specificity
Acronym:VIROFIGHT

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Back